Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05043324 · ClinicalTrials.gov registry record · Phase 4
Prevention and Treatment of Patient Before, During, and After Covid-19 Infection
A Phase 4 study, sponsored by Nguyen Thi Trieu, MD.
- Completed
- Registry status
- Phase 4
- Development phase
- 82
- Enrollment target
NCT05043324: Completed Phase 4 study, sponsored by Nguyen Thi Trieu, MD.
NCT05043324 is a Phase 4 study that has completed, run by Nguyen Thi Trieu, MD. The registered enrollment target is 82 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (84% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05043324, a Phase 4 study, has completed, sponsored by Nguyen Thi Trieu, MD.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 82 participants
- Enrollment target
Study Summary
AntiCov-220 prevents and treats before, during, and after infection with SARS-CoV-2. The composition is fractionally extracted from herbs (Ascorbic Acid, L-Arginine hydrochloride, Adenosma glutinosum extract, Eclipta prostrata extract, Phyllanthus urinaria extract, Impatiens balsamina extract, Rutin, Pregnenolone acetate, Allium sativum, Pyridoxine 5-phosphate, Cyanocobalamin), using flavonoids, isoflavonoids, and pregnenolone in combination with ascorbic acid as the key compounds in preventing and killing SARS-CoV-2; increase antibodies and protect cells; supplementing precursors to help the body strengthen antibodies and reduce the risk of infection; destroy spike protein, toxic protein, help prevent blood clots causing stroke; restore the physiological function of cells after virus infection; helps the body to stabilize the amount of cortisol in the blood as well as stabilize the production of specific antibodies. The composition participates in anti-inflammatory and cell-protecting processes, bringing blood cortisol, B-lymphocytes, Cyfra 21-1, WBC, CRP, fever, dyspnea, and other signs of respiratory tract inflammation to a normal state and normal limit.
Primary Outcome
COVID-19 is a contagious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Anticov-220 characterized by the targeting and destruction of COVID-19 * One case of Covid-19 infection with no severe change in a patient with HBeAg (+). * A case of HIV/AIDS turns back to HIV. Of the 35 follow-up subjects in this group, 20 were vaccinated and 15 were not. (The two cases mentioned above have not been vaccinated).
Interventions
- DRUG AntiCov-220
- DRUG AntiCov-220 (placebo)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2020-02-20 |
| Est. Completion | 2022-04-27 |
| Phase | Phase 4 |
What the finished NCT05043324 record still lists
NCT05043324 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 82 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (84% lower).
The record links to 0 conditions, and to 2 interventions - of which AntiCov-220 is the first listed.
NCT05043324 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05043324 about?
NCT05043324 is a clinical study titled "Prevention and Treatment of Patient Before, During, and After Covid-19 Infection". AntiCov-220 prevents and treats before, during, and after infection with SARS-CoV-2. The composition is fractionally extracted from herbs (Ascorbic Acid, L-Arginine hydrochloride, Adenosma glutinosum extract, Eclipta prostrata extract, Phyllanthus urinaria extract, Impatiens balsamina extract, Rutin...
What is the current status of trial NCT05043324?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 82 participants. The study started on 2020-02-20. Estimated completion is 2022-04-27.
What interventions are being tested in trial NCT05043324?
The interventions under investigation include: AntiCov-220 (DRUG), AntiCov-220 (placebo) (DRUG).
Who is sponsoring clinical trial NCT05043324?
This trial is sponsored by Nguyen Thi Trieu, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05043324's enrollment target sits among peer trials
82 939th of 2000 higher than 1,061 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03319901 · 82 participants · Phase 1
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
- NCT03493425 · 82 participants · Phase 2
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
- NCT04105270 · 82 participants · Phase 2
RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
- NCT04428658 · 82 participants · NA
Randomized Trial of Supplemental Synchronous and Asynchronous Telehealth to Improve Glycemic Control for Pediatric Patients With Type 1 Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI